Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S R Hesslewood

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
The British Journal of Radiology|December 1, 1984
Radiopharmaceuticals: reporting of defective products and abnormal in vivo distributionsS R Hesslewood
The Journal of Pharmacy and Pharmacology|December 1, 1975
Proceedings: Inducible tetracycline resistance in R+ and R- strains of Proteus mirabilisS R Hesslewood
European Journal of Nuclear Medicine|June 1, 1993
Adverse reaction to Tc-99 m DTPAS R Hesslewood
European Journal of Nuclear Medicine|April 17, 2001
European system for reporting adverse reactions to and defects in radiopharmaceuticals: annual report 1999S R Hesslewood
The Journal of Pharmacy and Pharmacology|December 1, 1974
Proceedings: Sensitivity of R+ strains of Proteus mirabilis to sodium desoxycholateS R Hesslewood
Nuclear Medicine Communications|August 1, 1990
Radiopharmaceuticals and Product Licences of RightA M Millar, S R Hesslewood
Nuclear Medicine Communications|June 1, 1988
Pattern of radiopharmaceutical administration to patients between 1982 and 1986S R Hesslewood, L K Harding
Journal of General Microbiology|November 1, 1974
Envelope alterations produced by R factors in Proteus mirabilisS R Hesslewood, J T Smith
European Journal of Nuclear Medicine|September 8, 1997
Frequency of adverse reactions to radiopharmaceuticals in EuropeS R Hesslewood, D H Keeling
Antonie Van Leeuwenhoek|January 1, 1974
Inhibition of R-factor-mediated beta-lactamase by Proteus mirabilisS R Hesslewood, J T Smith
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
The British Journal of Radiology|December 1, 1984
Radiopharmaceuticals: reporting of defective products and abnormal in vivo distributionsS R Hesslewood
The Journal of Pharmacy and Pharmacology|December 1, 1975
Proceedings: Inducible tetracycline resistance in R+ and R- strains of Proteus mirabilisS R Hesslewood
European Journal of Nuclear Medicine|June 1, 1993
Adverse reaction to Tc-99 m DTPAS R Hesslewood
European Journal of Nuclear Medicine|April 17, 2001
European system for reporting adverse reactions to and defects in radiopharmaceuticals: annual report 1999S R Hesslewood
The Journal of Pharmacy and Pharmacology|December 1, 1974
Proceedings: Sensitivity of R+ strains of Proteus mirabilis to sodium desoxycholateS R Hesslewood
Nuclear Medicine Communications|August 1, 1990
Radiopharmaceuticals and Product Licences of RightA M Millar, S R Hesslewood
Nuclear Medicine Communications|June 1, 1988
Pattern of radiopharmaceutical administration to patients between 1982 and 1986S R Hesslewood, L K Harding
Journal of General Microbiology|November 1, 1974
Envelope alterations produced by R factors in Proteus mirabilisS R Hesslewood, J T Smith
European Journal of Nuclear Medicine|September 8, 1997
Frequency of adverse reactions to radiopharmaceuticals in EuropeS R Hesslewood, D H Keeling
Antonie Van Leeuwenhoek|January 1, 1974
Inhibition of R-factor-mediated beta-lactamase by Proteus mirabilisS R Hesslewood, J T Smith
Pageof 3